Vifor Pharma divestment of finished drug product manufacturing business

Vifor Pharma Group closed its divestment transaction regarding its finished drug product manufacturing business with facilities in Fribourg, Ettingen (both in Switzerland) and Lisbon (Portugal) to CordenPharma, a full-service Contract Development & Manufacturing Organisation (CDMO) of APIs, Excipients, Drug Products, and associated Packaging services.

The Vifor Pharma Group is a global pharmaceutical company aiming to become the global leader in iron deficiency, nephrology and cardio-renal therapies. 

The companies have agreed not to disclose financial terms of the agreement. 

Kellerhals Carrard acted as legal advisor to Vifor Pharma on this transaction. The team was led by partner Emanuel Dettwiler (pictured) and comprised senior associate Sophie Holdt, associate Jon Oetiker (all corporate/m&a), and counsels Christine Bassanello (employment) and Philipp d’Hondt (notarial services). 

Vifor Pharma divestment of finished drug product manufacturing business

FabioAdmin

Legalcommunity.ch

Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).

For further information, please visit the Group’s website www.lcpublishinggroup.com

LC srl – Via Tolstoi 10 – 20146 Milano – Tel. 0236727659 – C.F./P.IVA 07619210961
REA 1971432 Registro delle Imprese di Milano – Cap. Soc. Euro 10.000,00 i.v.

Copyright 2022 © All rights Reserved. Design by Origami Creative Studio

SHARE

Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp
Share on email
Share on telegram